V. CLAIMS

1. A method for creating treatment composition for treating, inhibiting, reducing, preventing, or reversing wrinkles or baldness, the method comprising:

identifying the hair color, hair type, skin color, skin type, race, ethnicity of an end user;

obtaining mesenchymal stem cells (MSCs) from a targeted donor having the same hair type, hair color, skin color, and/or ethnicity as the end user; wherein the MSC further comprise a single nucleotide polymorphism (SNP) profile that indicates the donor will never experience wrinkles or baldness and can be gender, race, and ethnicity specific; and wherein the SNP comprises one or more SNPs present in one or more genes encoding Interleukin 18 (IL-18), Platelet Derived Growth Factor (PDGF) receptor (PDGFR) B (PDGFR-B), Tissue Inhibitors of Metalloprotease (TIMP) 1 (TIMP-1), TIMP-2, IL-23, Activin A, intrcellular adhesion molecule (ICAM-2), Plasminogen Activator Inhibitor-1 (PAI-1), Osteopontin (OPN), Insulin, Insulin growth factor binding protein four (IGF-BP4), Tumor Necrosis Factor (TNF) receptor (TNF-R), Neuregulin-1 B1 (NRG1-B1), Urokinase type Plasminogen Activator Receptor (uPAR), Ectodysplasin A2 receptor (XEDAR), follistatin, and/or activated leukocyte cell adhesion molecule (ALCAM); preferably, wherein the SNP comprises the IL-18 SNP rs1946518 (−607C>A) and/or rs187238 (−137G>C;

preparing a powder preparation comprising MSC derived secretomes, wherein the MSC derived secretomes are obtained from MSCs cultured under harsh wound healing conditions; and

adding the powder preparation to a base,

wherein the treatment composition is a topical composition or an injectable composition.

2. The method of claim 1, wherein the baldness comprises male pattern baldness, androgenetic alopecia, alopecia areata, cicatricial alopecia, telogen effluvium, or female pattern baldness.

3. The method of claim 2, wherein the treatment composition stimulates the activation of hair follicles to promote hair growth.

4. A treatment composition for treating, inhibiting, reducing, preventing, or reversing ~~a~~ wrinkles or baldness, the composition comprising:

a composition base; and

a powder preparation comprising mesenchymal stem cell (MSC) derived secretomes, wherein the MSC are derived from a donor having the same hair type, hair color, skin type, and/or skin color as an end user but with a single nucleotide polymorphism (SNP) profile that indicates the donor will never have wrinkles or baldness and can be gender, race, and ethnicity specific; wherein the SNP comprises one or more SNPs present in one or more genes encoding Interleukin 18 (IL-18), Platelet Derived Growth Factor (PDGF) receptor (PDGFR) B (PDGFR-B), Tissue Inhibitors of Metalloprotease (TIMP) 1 (TIMP-1), TIMP-2, IL-23, Activin A, intrcellular adhesion molecule (ICAM-2), Plasminogen Activator Inhibitor-1 (PAI-1), Osteopontin (OPN), Insulin, Insulin growth factor binding protein four (IGF-BP4), Tumor Necrosis Factor (TNF) receptor (TNF-R), Neuregulin-1 B1 (NRG1-B1), Urokinase type Plasminogen Activator Receptor (uPAR), Ectodysplasin A2 receptor (XEDAR),

follistatin, and/or activated leukocyte cell adhesion molecule (ALCAM); preferably, wherein the SNP comprises the IL-18 SNP rs1946518 (−607C>A) and/or rs187238 (−137G>C; and wherein the MSC derived secretomes are obtained from MSCs cultured under harsh wound healing conditions.

5. The treatment composition of claim 4, wherein the baldness comprises male pattern baldness, androgenetic alopecia, alopecia areata, cicatricial alopecia, telogen effluvium, or female pattern baldness.

6. A method of treating a hair disorder comprising administering to a subject any of the treatment compositions of claim 4 or 5.

7. A method of treating wrinkles comprising administering to a subject any of the treatment compositions of claim 4.

8. A method for creating a skin treatment composition for the treatment of wrinkles and specific for a specific skin color, race, type, or ethnicity, the method comprising:

identifying the skin color, skin type, race, and ethnicity of an end user;

obtaining mesenchymal stem cells (MSCs) from a targeted donor having the same skin color, skin type, race, and ethnicity as the end user based on the donor's appropriate single nucleotide polymorphism profile;

preparing a powder preparation comprising MSC derived secretomes, wherein the MSC derived secretomes are obtained from MSCs cultured under harsh wound healing conditions; and

adding the powder preparation to a cosmetic base.